Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-49 years.~* Give written informed consent to participate.~* Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory evaluation~* Females should fulfill one of the following criteria:~  * At least one year post-menopausal;~ * Surgically sterile;~ * Will use oral, implantable, transdermal or injectable contraceptives for 30 days prior to first vaccination and until 28 days after the booster vaccination; or~ * Willing to use another reliable form of contraception approved by the Investigator (e.g., intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, use of condom by the sexual partner or a sterile sexual partner) for 30 days prior to first vaccination and until 28 days after the booster vaccination.~* Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of first and booster vaccinations~* Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.~Exclusion Criteria:~* Persons under 18 years old or 50 years or older~* Persons with chronic illnesses such as cancer, diabetes, liver or kidney disease~* Persons taking medications or treatments that may adversely affect the immune system~* Persons with known allergy to eggs or other vaccine or adjuvant components~* Person currently pregnant, nursing mothers or planning a pregnancy within one month of vaccination~* Persons who have had a prior serious reaction to any influenza vaccine~* Persons with a known history of Guillain-Barré Syndrome~* Persons with a history of anaphylactic-type reaction to injected vaccines~* Persons with a history of drug or chemical abuse in the year preceding the study~* Persons who previously received an H5N1 influenza vaccine or who plan to receive an H5N1 influenza vaccine while participating in the study~* Persons who received a seasonal influenza vaccine six months prior to enrollment (may delay enrollment)~* Persons who received any other vaccine within one week prior to enrollment (may delay enrollment)~* Persons who have had a respiratory illness or illness with fever within three days of study enrollment (may delay enrollment)~* Persons currently participating in another research study involving any study medications (investigational drugs or vaccines).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- PanBlok 135µg No Adjuvant (Type: EXPERIMENTAL): 135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
- PanBlok 45µg No Adjuvant (Type: EXPERIMENTAL): 45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
- PanBlok 45µg and GLA 1.0µg, SE 2% (Type: EXPERIMENTAL): 45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
- PanBlok 15µg and GLA 1.0µg, SE 2% (Type: EXPERIMENTAL): 15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
- PanBlok 7.5µg and GLA 1.0µg, SE 2% (Type: EXPERIMENTAL): 7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
- PanBlok 3.8µg and GLA 1.0µg, SE 2% (Type: EXPERIMENTAL): 3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart

Based on this trial design, predict the completion outcome and termination type (if applicable).